Sat, Aug 23, 2014, 11:07 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cannabis Science, Inc. Message Board

  • heyyybulldoggg heyyybulldoggg Feb 29, 2012 10:24 AM Flag

    show me the product

    someone
    anyone

    all i see on website, when i click on product, is some buds of pot in a pill container.

    i see no exclusivity or patents or any product and all they talk about is pot.

    what is so unique with this company? why aren't they proudly explaining how and why they are so special over and above any other company that can do what they are doing?

    this stock was less than a penny in the last 52 weeks if i am not mistaken.

    i am not bashing. so don't bash me. i am trying to find out what is going on here.

    thanks folks.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • no intelligent posts

      come on people

      • 2 Replies to heyyybulldoggg
      • I think everyone is choosing to ignore and not help you considering all the bashing you did yesterday.


        We dont want you as a owner of CBIS stock.

      • Cancer Drug Market Evolves - Cannabis Science and ARIAD Pharmaceuticals Poised to
        Benefit

        The Paragon Report Provides Equity Research on Cannabis Science & ARIAD
        Pharmaceuticals

        NEW YORK, NY, Feb 27, 2012 (MARKETWIRE via COMTEX) -- Advances in cancer
        screening and treatment has caused the death rate from cancer to drop
        dramatically in recent years. Cancer death rates dropped by 1.8 percent per year
        in men and 1.6 percent per year in women between 2004 and 2008, according to the
        American Cancer Society's annual report on cancer statistics. The Paragon Report
        examines investing opportunities in the Healthcare sector and provides equity
        research on Cannabis Science Inc. (CBIS) & ARIAD Pharmaceuticals, Inc. (ARIA).
        Access to the full company reports can be found at:

        http://www.paragonreport.com/CBIS

        http://www.paragonreport.com/ARIA

        Death rates fell in all four of the most common cancers, lung, colon, breast and
        prostate, with lung cancer accounting for nearly 40 percent of the total drop in
        men and breast cancer account for 34 percent of the total decline in women, the
        American Cancer Society report finds.

        The U.S. FDA has been approving cancer drugs at a faster rate than its European
        counterpart (the EMA), Friends of Cancer Research reports. Between 2003 and 2010,
        the FDA not only approved more new cancer drugs than did the EMA, it approved
        these drugs more quickly: of 23 drugs approved by both agencies, the median time
        from marketing submission to FDA approval was 182 days vs. EMA approval of 350
        days according to the report.

        The Paragon Report provides investors with an excellent first step in their due
        diligence by providing daily trading ideas, and consolidating the public
        information available on them. For more investment research on the Healthcare
        sector register with us free at http://www.paragonreport.com and get exclusive
        access to our numerous stock reports and industry newsletters.

        ARIAD Pharmaceuticals' product pipeline includes Ponatinib, a pan BCR-ABL
        inhibitor in phase 2 clinical trial for applications in various hematological
        cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase (ALK)
        inhibitor in preclinical studies for the treatment of various cancers, including
        non-small cell lung cancer, lymphoma, and neuroblastoma.

        Cannabis Science, Inc., a development stage company, engages in the development,
        production, and commercialization of phytocannabinoid-based pharmaceutical
        products. Earlier this month the company introduced a fourth cancer patient with
        basal cell carcinoma (skin cancer) on his left nostril, who is self-administering
        a topical cannabis extract and having noticeable results.

    • i am fearful of buying in on the momentum that this could be halted for investigation and i could lose everything.

      maybe i am just a chicken. but i have had stocks before that have been halted and my nerves cannot take it.

      help enlighten me please with regard to why CBIS is such a steal at this price.

 
CBIS
0.073-0.001(-1.35%)Aug 22 3:52 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.